{"id":"es014","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, ES014 prevents its interaction with PD-L1, thereby unleashing T-cell mediated immune responses against cancer cells.","oneSentence":"ES014 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:46.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05717348","phase":"PHASE1","title":"A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elpiscience (Suzhou) Biopharma, Ltd.","startDate":"2023-02-24","conditions":"Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":120},{"nctId":"NCT06543056","phase":"PHASE2","title":"A Study of ES014 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-11-25","conditions":"Advanced Solid Tumor","enrollment":15},{"nctId":"NCT05381935","phase":"PHASE1","title":"A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors","status":"WITHDRAWN","sponsor":"Elpiscience Biopharma, Ltd.","startDate":"2023-04-21","conditions":"Advanced Solid Tumor","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ES014 for Injection"],"phase":"phase_2","status":"active","brandName":"ES014","genericName":"ES014","companyName":"Elpiscience (Suzhou) Biopharma, Ltd.","companyId":"elpiscience-suzhou-biopharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ES014 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}